Summary why it dropped $Novavax(NVAX)$
It Sees a Shortfall in Demand for Covid-19 Vaccines. Novavax slumped more than 31% Tuesday after the Covid-19 vaccine maker slashed its guidance for 2022 revenue.
they said it expects revenue this year of $2 billion to $2.3 billion, down from previous expectations of $4 billion to $5 billion.
my opinion ; They're about two years late to the party and now nobody cares about Covid anymore. All a hoax just like the flu shot designed to line the pockets of drug companies.
If u were to see the options with 30% buffer with2% premium so it's a dangerous buy
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments